Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer
Open Access
- 11 March 2012
- journal article
- research article
- Published by Wiley in Molecular Biology International
- Vol. 2012, 1-8
Abstract
Promoter hypermethylation, a widely studied epigenetic event known to influence gene expression levels, has been proposed as a potential biomarker in multiple types of cancer. Clinical diagnostic biomarkers are needed for reliable prediction of bladder cancer recurrence. In this paper, DNA promoter methylation of five C-terminal Ras-association family members (RASSF1A, RASSF2A, RASSF4, RASSF5, and RASSF6) was studied in 64 formalin-fixed paraffin-embedded (FFPE) bladder cancer and normal adjacent tissues using methylation-specific high-resolution melting (MS-HRM) analysis. Results showed that 73% (30/41) of transitional cell carcinoma, 100% (3/3) of squamous cell carcinoma, and 100% (4/4) of small cell carcinoma demonstrated promoter methylation of the RASSF1A or RASSF2A gene, but only 6% (1/16) of normal tissues had promoter methylation of RASSF genes. Testing positive for hypermethylation of RASSF1A or RASSF2A promoter provided 77% sensitivity and 94% specificity for identification of cancer tissues with an area under the curve of 0.854, suggesting that promoter methylation analysis of RASSF1A and RASSF2A genes has potential for use as a recurrence biomarker for bladder cancer patients.Keywords
Funding Information
- National Cancer Institute (R01CA108633, RC2CA148190, P30 CA16058, LA2510/1-1)
- National Cancer Institute (R01CA108633, RC2CA148190, P30 CA16058, LA2510/1-1)
- National Cancer Institute (R01CA108633, RC2CA148190, P30 CA16058, LA2510/1-1)
- Deutsche Forschungsgemeinschaft (R01CA108633, RC2CA148190, P30 CA16058, LA2510/1-1)
This publication has 29 references indexed in Scilit:
- Assessment of NORE1A as a putative tumor suppressor in human neuroblastomaInternational Journal of Cancer, 2008
- A Novel Set of DNA Methylation Markers in Urine Sediments for Sensitive/Specific Detection of Bladder CancerClinical Cancer Research, 2007
- The Ras-association domain family (RASSF) members and their role in human tumourigenesisBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2007
- RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesisMolecular Cancer, 2007
- Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancerLung Cancer, 2007
- Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinomaInternational Journal of Cancer, 2006
- RASSF4/AD037 Is a Potential Ras Effector/Tumor Suppressor of the RASSF FamilyCancer Research, 2004
- Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomasOncogene, 2004
- Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patientsInternational Journal of Cancer, 2003
- Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patientsOncogene, 2003